Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Four Point Test Flags Patients at Risk of Dying from Clostridium difficile Infection

By LabMedica International staff writers
Posted on 20 Aug 2013
Analysis of metabolic and mortality data from a group of patients with Clostridium difficile infections has allowed the establishment of a prediction rule based on clinical variables to aid hospital physicians to rank incoming patients according to risk of dying from the infection.

C. More...
difficile is an anaerobic, spore forming, rod shaped bacterium, and is a prevalent cause of nosocomial infection. Furthermore, antibiotic resistant strains of C. difficile are a growing problem in healthcare systems. Recent C. difficile epidemics have been caused by hypervirulent strains, which became resistant to the fluoroquinolones soon after their introduction into the healthcare setting.

When C. difficile bacteria are introduced into a colon in which the normal gut flora has been destroyed (usually after a broad-spectrum antibiotic such as clindamycin has been used), the gut becomes overrun with C. difficile. This overpopulation is harmful because the bacteria release toxins that can cause bloating and diarrhea, with abdominal pain, which may become severe. C. difficile infections are the most common cause of pseudomembranous colitis, and in rare cases, this can progress to toxic megacolon, which can be life threatening.

Investigators at the University of Exeter (United Kingdom) and the Royal Devon & Exeter Hospital (United Kingdom) evaluated over 186 variables collated retrospectively from clinical data for 213 patients. From this data, they devised a simple four variable prediction rule that included serum albumin levels, respiratory rate, C-reactive protein, and white cell count. Threshold levels of these variables were associated with an increased risk of all-cause mortality.

Contributing author Dr. Steve Michell, senior lecturer in molecular microbiology at the University of Exeter, said, "Our findings are exciting because they identify a simple, accurate, and robust method to identify those patients who are at risk of dying from a C difficile infection. The clinical variables identified are easily measurable, using tests that are commonly carried out in hospital. The results of our study strengthen the evidence for establishing the use of this rule in clinical settings: the benefits to patient well-being, the efficient management of infection in hospital and potential savings to the NHS and other health services around the world, would be immense."

The study was published in the July 12, 2013, online edition of the journal BMC Infectious Diseases.

Related Links:
University of Exeter
Royal Devon & Exeter Hospital


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.